Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY1862864 in Relapsed/Refractory CD22+ NHL
NCT02581878Phase 1Completed
- Sponsor
- Bayer
- Start
- Nov 2015
- Primary completion
- Nov 2019
- Modality
- Alpha Emitters, Monoclonal Antibodies, Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of BAY 1862864 in Non-Hodgkin lymphoma (NHL) (5 cohorts), sponsored by Bayer. Primary endpoint: Maximum Tolerated Dose at 6 weeks. Started Nov 2015; status: completed.
02
Drugs
BAY 1862864
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02581878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581878.